Sanuwave Health price target raised to $55 from $54 at Roth Capital

Roth Capital analyst Kyle Bauser raised the firm’s price target on Sanuwave Health (SNWV) to $55 from $54 and keeps a Buy rating on the shares. The firm cites the company having received a $5.0M non-dilutive cash payment from a third-party licensee in connection with the full transfer of ownership of its patent portfolio related to intravascular shockwave applications. This action improves Sanuwave’s balance sheet ahead of its expected debt refinancing in the coming days and also increases the likelihood of future patent infringement recoveries as well as the company’s position as a takeout candidate, the analyst tells investors in a research note.